FAQ/Help |
Calendar |
Search |
Today's Posts |
07-28-2016, 10:18 AM | #1 | ||
|
|||
Member
|
Public Release: 27-Jul-2016
The TNP, led by Charbel Moussa, MD, PhD, has identified several tyrosine kinase, which appear to play a role in neurodegeneration, protein clearance and inflammation. This work has led to clinical trials with the cancer drug nilotinib in both Parkinson's and Alzheimer's disease set to begin this summer. TORONTO - An FDA approved drug to treat renal cell carcinoma appears to reduce levels of a toxic brain protein linked to dementia in Alzheimer's and Parkinson's diseases when given to animals. This finding is the latest from Georgetown University Medical Center's Translational Neurotherapeutics Program (TNP) examining tyrosine kinase inhibitors in the treatment of neurodegenerative diseases. More evidence in quest to repurpose cancer drugs for Alzheimer's disease | EurekAlert! Science News |
||
Reply With Quote |
|
|
Similar Threads | ||||
Thread | Forum | |||
Six month follow up on Nilotinib trial. | Parkinson's Disease | |||
Michael Fox Partners to Assess Clinical Development of Nilotinib in Parkinson's | Parkinson's Disease | |||
Compassionate use of Nilotinib for treating Parkinson's & Lewy Body Disease Patients | Parkinson's Disease |